Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
August 17, 2018

NIH starts Phase l trial of rZIKV/D4Δ30-713 for Zika virus infection

The US National Institutes of Health (NIH) has started a Phase l clinical trial of rZIKV/D4Δ30-713 vaccine for the prevention of Zika virus infection.

The US National Institutes of Health (NIH) has started a Phase l clinical trial of rZIKV/D4Δ30-713 vaccine for the prevention of Zika virus infection.

The randomised trial is designed to investigate the safety, reactogenicity, and immunogenicity of a single dose of the live attenuated Zika vaccine rZIKV/D4Δ30-713 in adults with no history of previous flavivirus infection such as Zika, dengue, or yellow fever.

It is expected to enrol 28 healthy, non-pregnant adults aged 18 to 50 at two sites in the US, including Johns Hopkins Bloomberg School of Public Health Center for Immunization Research in Baltimore, Maryland, and the Vaccine Testing Center at the Larner College of Medicine at the University of Vermont in Burlington.

During the trial, the subjects will be randomly assigned to receive a single subcutaneous dose of rZIKV/D4Δ30-713 or a placebo.

Of the total subjects, 20 will receive rZIKV/D4Δ30-713, while the remaining eight will receive placebo.

“During the trial, the subjects will be randomly assigned to receive a single subcutaneous dose of rZIKV/D4Δ30-713 or a placebo.”

Following the vaccination, the subjects will receive a diary card to record their temperature at home at certain intervals.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

For the next six months, the subjects will visit the clinic periodically for physical examinations and to provide blood and other samples.

NIH unit National Institute of Allergy and Infectious Diseases (NIAID) will sponsor the trial.

NIAID director Anthony Fauci said: “Zika virus infection remains a significant threat to pregnant women and their developing fetuses, and we can expect to see periodic outbreaks and cases in areas where Aedes aegypti mosquitoes thrive.”

In addition, NIAID Laboratory of Viral Diseases PhD holder Dr. Stephen Whitehead has led the efforts to develop the investigational rZIKV/D4Δ30-713 vaccine that could help prevent the infection of Zika virus.

Zika virus is primarily caused by the bite of an infected mosquito or can be transmitted through sex.

There are currently no licensed vaccines available for Zika virus infection.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU